



Georgia
Medicaid Fee-For-Service (FFS)
2018 Drug Utilization Review (DUR)

Table of Contents

Section I – Number of Beneficiaries	1
1. On average, how many beneficiaries are enrolled in your state's Medicaid Fee-For-Service (FFS) program that have a pharmacy benefit?.....	1
2. On average, how many of your state's Medicaid beneficiaries are enrolled in managed care plan(s)?.....	1
Section II - Prospective DUR (ProDUR)	1
1. Indicate the type of your pharmacy POS Vendor.	1
a. Vendor Name	1
b. Is the POS vendor also the MMIS fiscal agent?.....	1
2. Identify prospective DUR criteria source.	1
3. Are new ProDUR criteria approved by the DUR Board?	1
4. When the pharmacist receives a level-one ProDUR alert message that requires a pharmacist's review, does your system allow the pharmacist to override the alert using the "NCPDP drug use evaluation codes" (reason for service, professional service and resolution)?	1
5. Do you receive and review follow-up periodic reports providing individual pharmacy provider DUR alert override activity in summary and/or in detail?	1
a. If "Yes," how often?	1
b. If you receive reports, do you follow up with those providers who routinely override with interventions?	1
6. Early Refill.....	2
a. At what percent threshold do you set the system to edit?	2
b. For non-controlled drugs:	2
c. For controlled drugs:.....	2
7. When the pharmacist receives an early refill DUR alert message that requires the pharmacist's review, does your state's policy allow the pharmacist to override for situations such as (check all that apply):	2
8. Does your system have an accumulation edit to prevent patients from continuously filling prescriptions early? ...	2
9. Does the state Medicaid agency or the state's Board of Pharmacy have any policy prohibiting the auto-refill process that occurs at the POS (i.e. must obtain beneficiary's consent prior to enrolling in the auto-refill program)? ...	2
10. Does the state Medicaid agency have any policy that provides for the synchronization of prescription refills (i.e. if the patient wants and pharmacy provider permits the patient to obtain non-controlled, chronic medication refills at the same time, the state would allow this to occur to prevent the beneficiary from making multiple trips to the pharmacy within the same month)?	3
11. Please list the requested data in each category in Table 1 - Top Drug Claims Data Reviewed by the DUR Board that follows	3

12. Section 1927(g)(A) of the Social Security Act requires that the pharmacist offer patient counseling at the time of dispensing. Who in your state has responsibility for monitoring compliance with the oral counseling requirement? Check all that apply:.....	4
13. Attachment 1 – Pharmacy Oral Counseling Compliance Report	4
Section III - RETROSPECTIVE DUR (RetroDUR)	4
1. Identify, by name and type, the vendor that performed your RetroDUR activities during the time period covered by this report.....	5
a. Is the RetroDUR vendor also the Medicaid fiscal agent?.....	5
b. Is the RetroDUR vendor also the developer/supplier of your retrospective DUR criteria?	5
2. Who reviews and approves the RetroDUR criteria?	5
3. Attachment 2 – Retrospective DUR Educational Outreach Summary	5
Section IV - DUR BOARD ACTIVITY	5
1. Attachment 3 – Summary of DUR Board Activities.....	5
2. Does your state have an approved CMS Medication Therapy Management Program?	6
a. Have you performed an analysis of the program's effectiveness?	6
b. Is your DUR Board involved with this program?	6
Section V - PHYSICIAN ADMINISTERED DRUGS	6
1. ProDUR?	6
2. RetroDUR?.....	6
Section VI - GENERIC POLICY AND UTILIZATION DATA	6
1. Attachment 4 - Generic Drug Substitution Policies	6
2. In addition to the requirement that the prescriber write in his own handwriting "Brand Medically Necessary" for a brand name drug to be dispensed in lieu of the generic equivalent, does your state have a more restrictive requirement?	7
3. Indicate the generic utilization percentage for all covered outpatient drugs paid during this reporting period, using the computation instructions in Table 2 – Generic Utilization Data.	7
4. Indicate the percentage dollars paid for generic covered outpatient drugs in relation to all covered outpatient drug claims paid during this reporting period using the computation instructions in Table 2 - Generic Drug Utilization Data.....	7
Section VII - PROGRAM EVALUATION / COST SAVINGS / COST AVOIDANCE	8
1. Did your state conduct a DUR program evaluation of the estimated cost savings/cost avoidance?	8
2. Please provide your ProDUR and RetroDUR program cost savings/cost avoidance in the chart below	8
3. The Estimated Percent Impact was generated by dividing the Grand Total Estimated Avoided Costs from Question 2 above by the Total Dollar Amount provided in Section VI, Question 4, then multiplying this value by 100.	8
4. Attachment 5 – Cost Savings/Cost Avoidance Methodology	8
Section VIII - FRAUD, WASTE AND ABUSE DETECTION	9
A. LOCK-IN or PATIENT REVIEW AND RESTRICTION PROGRAMS.....	9

1. Do you have a documented process in place that identifies potential fraud or abuse of controlled drugs by beneficiaries?	9
2. Do you have a Lock-In program for beneficiaries with potential misuse or abuse of controlled substances?	9
a. What criteria does your state use to identify candidates for Lock-In? Check all that apply:	9
b. Do you have the capability to restrict the beneficiary to:	9
c. What is the usual Lock-In time period?	9
d. On average, what percentage of the FFS population is in Lock-In status annually?	9
e. Please provide an estimate of the savings attributed to the Lock-In program for the fiscal year under review as part of Attachment 5.	9
3. Do you have a documented process in place that identifies possible fraud or abuse of controlled drugs by prescribers?.....	9
4. Do you have a documented process in place that identifies potential fraud or abuse of controlled drugs by pharmacy providers?	10
5. Do you have a documented process in place that identifies and/or prevents potential fraud or abuse of non-controlled drugs by beneficiaries?.....	10
B. PRESCRIPTION DRUG MONITORING PROGRAM (PDMP)	10
1. Does your state have a Prescription Drug Monitoring Program (PDMP)?	10
a. Does your agency have the ability to query the state's PDMP database?	10
b. Do you require prescribers (in your provider agreement with the agency) to access the PDMP patient history before prescribing controlled substances?	10
c. Are there barriers that hinder the agency from fully accessing the PDMP that prevent the program from being utilized the way it was intended to be to curb abuse?	10
2. Have you had any changes to your state's Prescription Drug Monitoring Program during this reporting period that have improved the agency's ability to access PDMP data?	11
C. PAIN MANAGEMENT CONTROLS	11
1. Does your program obtain the DEA Active Controlled Substance Registrant's File in order to identify prescribers not authorized to prescribe controlled drugs?	11
a. Do you apply this DEA file to your ProDUR POS edits to prevent unauthorized prescribing?	11
b. Do you apply this DEA file to your RetroDUR reviews?	11
2. Do you have a measure (i.e. prior authorization, quantity limits) in place to either monitor or manage the prescribing of methadone for pain management?	11
D. OPIOIDS	11
1. Do you currently have a POS edit in place to limit the quantity dispensed of an initial opioid prescription?	12
a. Is there more than one quantity limit for the various opioids?.....	12
b. What is your maximum number of days allowed for an initial opioid prescription?	12
c. Does this day limit apply to all opioid prescriptions?	12
2. For subsequent prescriptions, do you have POS edits in place to limit the quantity dispensed of short-acting opioids?	12

3. Do you currently have POS edits in place to limit the quantity dispensed of long-acting opioids?	12
4. Do you have measures other than restricted quantities and days supply in place to either monitor or manage the prescribing of opioids?	12
5. Do you currently have edits in place to monitor opioids and benzodiazepines being used concurrently?	13
6. Do you perform any RetroDUR activity and/or provider education in regard to beneficiaries with a diagnosis or history of opioid use disorder (OUD), or opioid poisoning diagnosis?	13
7. Does your state Medicaid agency develop and provide prescribers with pain management or opioid prescribing guidelines?	13
8. Do you have a drug utilization management strategy that supports abuse deterrent opioid use to prevent opioid misuse and abuse (i.e. presence of an abuse deterrent opioid with preferred status on your preferred drug list)?.....	13
E. MORPHINE EQUIVALENT DAILY DOSE (MEDD)	13
1. Have you set recommended maximum morphine equivalent daily dose measures?.....	13
a. What is your maximum morphine equivalent daily dose limit in milligrams?	14
b. Please explain (i.e. are you in the process of tapering patients to achieve this limit?).....	14
2. Do you provide information to your prescribers on how to calculate the morphine equivalent daily dosage or do you provide a calculator developed elsewhere?	14
a. Please name the developer of the calculator:	14
b. How is the information disseminated? Check all that apply:	14
3. Do you have an edit in your POS system that alerts the pharmacy provider that the morphine equivalent daily dose prescribed has been exceeded?	14
F. BUPRENORPHINE, NALOXONE, BUPRENORPHINE/NALOXONE COMBINATIONS and METHADONE for OPIOID USE DISORDER (OUD)	14
1. Does your agency set total mg per day limits on the use of buprenorphine and buprenorphine/naloxone combination drugs?	14
2. What are your limitations on the allowable length of this treatment?.....	14
3. Do you require that the maximum mg per day allowable be reduced after a set period of time?	14
a. What is your reduced (maintenance) dosage?	14
b. What are your limitations on the allowable length of the reduced dosage treatment?	15
4. Do you have at least one buprenorphine/naloxone combination product available without prior authorization?	15
5. Do you currently have edits in place to monitor opioids being used concurrently with any buprenorphine drug?	15
6. Do you have at least one naloxone opioid overdose product available without prior authorization?	15
7. Does your state board of pharmacy and/or state Medicaid agency allow pharmacists to dispense naloxone prescribed independently or by collaborative practice agreements, standing orders, or other predetermined protocols?	15
8. Does your state agency cover Methadone for a substance use disorder (i.e. Methadone Treatment Center)?.....	15
G. ANTIPSYCHOTICS / STIMULANTS	15
ANTIPSYCHOTICS	15

1. Do you currently have restrictions in place to limit the quantity of antipsychotics? Enter restrictions other than quantity limits in the text box below, or N/A.	15
2. Do you have a documented program in place to either manage or monitor the appropriate use of antipsychotic drugs in children?.....	15
a. Do you either manage or monitor:	16
b. Do you have edits in place to monitor (check all that apply):	16
c. Please briefly explain the specifics of your antipsychotic monitoring program(s).....	16
STIMULANTS	16
3. Do you currently have restrictions in place to limit the quantity of stimulants?	16
4. Do you have a documented program in place to either manage or monitor the appropriate use of stimulant drugs in children?.....	16
a. Do you either manage or monitor:	16
b. Do you have edits in place to monitor (check all that apply):	16
c. Please briefly explain the specifics of your documented stimulant monitoring program(s).	16
Section IX - INNOVATIVE PRACTICES	16
1. Attachment 6 – Innovative Practices Narrative	16
Section X - E-PRESCRIBING	17
1. Does your MMIS or pharmacy vendor have a portal to electronically provide patient drug history data and pharmacy coverage limitations to a prescriber prior to prescribing upon inquiry?	17
2. Does your system use the NCPDP Origin Code that indicates the prescription source?.....	17
Section XI - MANAGED CARE ORGANIZATIONS (MCOs)	17
1. How many MCOs are enrolled in your state Medicaid program?	17
2. Is your pharmacy program included in the capitation rate (carved in)?	17
3. Does the state set requirements for the MCO's pharmacy benefit (e.g. same PDL, same ProDUR/RetroDUR)?	18
a. Please check all requirements that apply below:	18
b. Please briefly explain your policy.....	18
4. Did all of your managed care plans submit their DUR reports?	18
Section XII – EXECUTIVE SUMMARY	18
1. Attachment 8 – Executive Summary.....	18

PLEASE NOTE: This is a standalone report posted on Medicaid.gov. Attachments to the report have not been posted. To obtain related report attachments, please contact CMSDUR@cms.hhs.gov.

Georgia DUR 2018 FFS Individual State Report

Section I – Number of Beneficiaries

Question	Response
1. On average, how many beneficiaries are enrolled in your state's Medicaid Fee-For-Service (FFS) program that have a pharmacy benefit?	436,095
2. On average, how many of your state's Medicaid beneficiaries are enrolled in managed care plan(s)?	1,368,234

Section II - Prospective DUR (ProDUR)

Question	Response
1. Indicate the type of your pharmacy POS Vendor.	Contractor
a. Vendor Name	OptumRx
b. Is the POS vendor also the MMIS fiscal agent?	No
2. Identify prospective DUR criteria source.	Medi-Span
If "Other," please Specify	N/A
3. Are new ProDUR criteria approved by the DUR Board?	No
If No, please explain	Criteria is from MediSpan
4. When the pharmacist receives a level-one ProDUR alert message that requires a pharmacist's review, does your system allow the pharmacist to override the alert using the "NCPDP drug use evaluation codes" (reason for service, professional service and resolution)?	Yes
If "Partial," please explain	N/A
5. Do you receive and review follow-up periodic reports providing individual pharmacy provider DUR alert override activity in summary and/or in detail?	Yes
If "No," please explain	N/A
a. If "Yes," how often?	Quarterly
If "Other," please explain	N/A
b. If you receive reports, do you follow up with those providers who routinely override with interventions?	No
If "No," please explain	While the functionality to override is present, we currently do not require soft edit overrides.

Question	Response
If "Yes," by what method do you follow up?	N/A
If "Other," please explain.	N/A
6. Early Refill	
a. At what percent threshold do you set the system to edit?	
i) <i>Non-controlled drugs:</i>	75.00%
ii) <i>Schedule II controlled drugs:</i>	85.00%
iii) <i>Schedule III through V controlled drugs:</i>	85.00%
b. For non-controlled drugs:	
When an early refill message occurs, does the state require prior authorization?	Yes
If "Yes," who obtains authorization?	Either
If "No," can the pharmacist override at the point of service?	N/A
c. For controlled drugs:	
When an early refill message occurs, does the state require prior authorization?	Yes
If "Yes," who obtains authorization?	Either
If "No," can the pharmacist override at the point of service?	N/A
7. When the pharmacist receives an early refill DUR alert message that requires the pharmacist's review, does your state's policy allow the pharmacist to override for situations such as (check all that apply):	Other
If "Other," please explain.	Pharmacists not allowed to override early refill
8. Does your system have an accumulation edit to prevent patients from continuously filling prescriptions early?	Yes
If "Yes," please explain your edit.	Refill-too-soon edit, which allows patients to only obtain next fill if 75% of previous fill would be completed by that time.
If "No," do you plan to implement this edit?	N/A
9. Does the state Medicaid agency or the state's Board of Pharmacy have any policy prohibiting the auto-refill process that occurs at the POS (i.e. must obtain beneficiary's consent prior to enrolling in the auto-refill program)?	Yes

Question	Response
10. Does the state Medicaid agency have any policy that provides for the synchronization of prescription refills (i.e. if the patient wants and pharmacy provider permits the patient to obtain non-controlled, chronic medication refills at the same time, the state would allow this to occur to prevent the beneficiary from making multiple trips to the pharmacy within the same month)?	No
11. Please list the requested data in each category in Table 1 - Top Drug Claims Data Reviewed by the DUR Board that follows	

Table 1 – Top Drug Claims Data Reviewed by the DUR Board

Top 10 Prior Authorization (PA) Requests by Drug Name	Top 10 Prior Authorization (PA) Requests by Drug Class	Top 5 Claim Denial Reasons Other Than Eligibility (i.e. Quantity Limits, Early Refill, PA, Therapeutic Duplications, Age Edits)	Top 10 Drug Names by Amount Paid	% of Total Spent for Drugs by Amount Paid From data in Column 4, determine the % of total drug spend.	Top 10 Drug Names by Claim Count	Drugs by Claim Count % of Total Claims From data in Column 6, determine the % of total claims.
OMEPRAZOLE	ULCER DRUGS	Prod/Service Not Covered	INVEGA SUSTENNA	3.01%	GABAPENTIN	2.22%
PANTOPRAZOLE SODIUM	ANTIPSYCHOTICS/ANTIMANIC AGENTS	Plan Limitations Exceeded	LYRICA	2.33%	AMLODIPINE BESYLATE	2.22%
ARIPIRAZOLE	ANTIDIABETICS	Prior Authorization Reqr'd	GENVOYA	2.33%	LISINOPRIL	2.17%
MONTELUKAST SODIUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	DUR Reject Error	HARVONI	2.14%	PROVENTIL HFA	1.99%
INVEGA SUSTENNA	DERMATOLOGICALS	Prescriber is Not Covered	ADVAIR DISKUS	1.79%	ATORVASTATIN CALCIUM	1.93%
VOLTAREN	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIA		PROVENTIL HFA	1.64%	HYDROCODONE/ACETAMINOPHEN	1.83%
ADDERALL XR	ANTICONVULSANTS		LANTUS	1.62%	RANITIDINE HCL	1.45%
AMPHETAMINE/DEXTROAMPHETAMINE	GASTROINTESTINAL AGENTS - MISC.		SYMBICORT	1.59%	LEVOTHYROXINE SODIUM	1.31%
LINZESS	ANALGESICS - ANTI-		TRIUMEQ	1.54%	METFORMIN HCL	1.25%

Top 10 Prior Authorization (PA) Requests by Drug Name	Top 10 Prior Authorization (PA) Requests by Drug Class	Top 5 Claim Denial Reasons Other Than Eligibility (i.e. Quantity Limits, Early Refill, PA, Therapeutic Duplications, Age Edits)	Top 10 Drug Names by Amount Paid	% of Total Spent for Drugs by Amount Paid From data in Column 4, determine the % of total drug spend.	Top 10 Drug Names by Claim Count	Drugs by Claim Count % of Total Claims From data in Column 6, determine the % of total claims.
	INFLAMMATORY					
ONFI	ANTIVIRALS		HUMIRA PEN	1.51%	FLUTICASONE PROPIONATE	1.21%

Question	Response
12. Section 1927(g)(A) of the Social Security Act requires that the pharmacist offer patient counseling at the time of dispensing. Who in your state has responsibility for monitoring compliance with the oral counseling requirement? Check all that apply:	State Board of Pharmacy
If "Other," please explain:	N/A
13. Attachment 1 – Pharmacy Oral Counseling Compliance Report This attachment reports the monitoring of pharmacy compliance with all prospective DUR requirements performed by the State Medicaid Agency, the State Board of Pharmacy, or other entity responsible for monitoring pharmacy activities. If the State Medicaid Agency itself monitors compliance with these requirements, it may provide a survey of a random sample of pharmacies with regard to compliance with the Omnibus Budget Reduction Act (OBRA) of 1990 prospective DUR requirement. This report details state efforts to monitor pharmacy compliance with the oral counseling requirement. This attachment should describe in detail the monitoring efforts that were performed and how effective these efforts were in the fiscal year reported. Does the state have Attachment 1 described above to upload?	Yes

Section III - RETROSPECTIVE DUR (RetroDUR)

Question	Response
1. Identify, by name and type, the vendor that performed your RetroDUR activities during the time period covered by this report.	
Organization Name	NorthStar Healthcare Consulting
Organization Type	Company
a. Is the RetroDUR vendor also the Medicaid fiscal agent?	No
b. Is the RetroDUR vendor also the developer/supplier of your retrospective DUR criteria?	Yes
"No," please explain	N/A
2. Who reviews and approves the RetroDUR criteria?	State DUR board
"Other," please explain	N/A
3. Attachment 2 – Retrospective DUR Educational Outreach Summary This is a year-end summary report on RetroDUR screening and educational interventions. The year-end summary reports should be limited to the TOP 10 problems with the largest number of exceptions. The results of RetroDUR screening and interventions should be included. Does the state have Attachment 2 described above to upload?	Yes

Section IV - DUR BOARD ACTIVITY

Question	Response
1. Attachment 3 – Summary of DUR Board Activities. This summary should be a brief descriptive report on DUR Board activities during the fiscal year reported. This summary should: a. Indicate the number of DUR Board meetings held. b. List additions/deletions to DUR Board approved criteria. i. For prospective DUR, list problem type/drug combinations added or deleted. ii. For retrospective DUR, list therapeutic categories added or deleted. c. Describe Board policies that establish whether and how results of prospective DUR screening are used to adjust retrospective DUR screens. Also, describe policies that establish whether and how results of	Yes

Question	Response
retrospective DUR screening are used to adjust prospective DUR screens. d. Describe DUR Board involvement in the DUR education program (e.g., newsletters, continuing education, etc.). Also, describe policies adopted to determine mix of patient or provider specific intervention types (e.g., letters, face-to-face visits, increased monitoring). Does the state have Attachment 3 described above to upload?	
2. Does your state have an approved CMS Medication Therapy Management Program?	No
a. Have you performed an analysis of the program's effectiveness?	N/A
"Yes," please provide a brief summary of your findings.	N/A
b. Is your DUR Board involved with this program?	N/A
If the answer to question 2 is "No," are you planning to develop and implement a program?	No

Section V - PHYSICIAN ADMINISTERED DRUGS

The Deficit Reduction Act requires collection of NDC numbers for covered outpatient physician administered drugs. These drugs are paid through the physician and hospital programs. Has your MIMIS been designed to incorporate this data into your DUR criteria for:

Question	Response
1. ProDUR?	Yes
If "No," do you have a plan to include this information in your DUR criteria in the future?	N/A
2. RetroDUR?	Yes
If "No," do you have a plan to include this information in your DUR criteria in the future?	N/A

Section VI - GENERIC POLICY AND UTILIZATION DATA

Question	Response
1. Attachment 4 - Generic Drug Substitution Policies Please report any factors that could affect your generic utilization percentage and include any relevant documentation. Does the state have Attachment 4 described above to upload?	Yes

Question	Response
2. In addition to the requirement that the prescriber write in his own handwriting "Brand Medically Necessary" for a brand name drug to be dispensed in lieu of the generic equivalent, does your state have a more restrictive requirement?	Yes
If "Yes," check all that apply.	Prior authorization is required
If "Other," please explain.	N/A

Complete Table 2 - Generic Drug Utilization Data and answer Questions 3 and 4 below.

	Single Source (S) Drugs	Non-Innovator (N) Drugs	Innovator Multi-Source (I) Drugs
Total Number of Claims	767,904	6,134,501	345,262
Total Reimbursement Amount Less Co-Pay	\$570,402,000	\$105,859,000	\$75,126,000

Question	Response
3. Indicate the generic utilization percentage for all covered outpatient drugs paid during this reporting period, using the computation instructions in Table 2 – Generic Utilization Data.	
Number of Generic Claims	6,134,501
Total Number of Claims	7,247,667
Generic Utilization Percentage	84.64%
4. Indicate the percentage dollars paid for generic covered outpatient drugs in relation to all covered outpatient drug claims paid during this reporting period using the computation instructions in Table 2 - Generic Drug Utilization Data.	
Generic Dollars	\$105,859,000
Total Dollars	\$751,387,000

Question	Response
Generic Expenditure Percentage	14.09%

Section VII - PROGRAM EVALUATION / COST SAVINGS / COST AVOIDANCE

Question	Response
1. Did your state conduct a DUR program evaluation of the estimated cost savings/cost avoidance? If "Yes," identify, by name and type, the institution that conducted the program evaluation.	Yes
Institution Name	OptumRx
Institution Type	Company
2. Please provide your ProDUR and RetroDUR program cost savings/cost avoidance in the chart below	

	Data
ProDUR Total Estimated Avoided Costs	\$92,576,885.19
RetroDUR Total Estimated Avoided Costs	\$1.00
Other Cost Avoidance	\$1.00
Grand Total Estimated Avoided Costs	\$92,576,887.19

Question	Response
3. The Estimated Percent Impact was generated by dividing the Grand Total Estimated Avoided Costs from Question 2 above by the Total Dollar Amount provided in Section VI, Question 4, then multiplying this value by 100. Estimated Percent Impact	12.32%
4. Attachment 5 – Cost Savings/Cost Avoidance Methodology Include copy of program evaluations/cost savings estimates prepared by state or contractor noting methodology used. Does the state have Attachment 5 described above to upload?	Yes

Section VIII - FRAUD, WASTE AND ABUSE DETECTION

A. LOCK-IN or PATIENT REVIEW AND RESTRICTION PROGRAMS

Question	Response
1. Do you have a documented process in place that identifies potential fraud or abuse of controlled drugs by beneficiaries?	Yes
If "Yes," what actions does this process initiate? Check all that apply:	Deny claims and require prior authorization, Refer to Lock-In Program, Refer to Program Integrity Unit
"Other," please explain	N/A
2. Do you have a Lock-In program for beneficiaries with potential misuse or abuse of controlled substances? If the answer to question 2 is "Yes," please continue	Yes
a. What criteria does your state use to identify candidates for Lock-In? Check all that apply:	Number of controlled substances (CS), Different prescribers of CS, Multiple pharmacies, Number days' supply of CS, Exclusivity of short acting opioids, Multiple ER visits, PDMP data
"Other," please explain	N/A
b. Do you have the capability to restrict the beneficiary to:	
<i>i. Prescriber only</i>	Yes
<i>ii. Pharmacy only</i>	Yes
<i>iii. Prescriber and Pharmacy only</i>	Yes
c. What is the usual Lock-In time period?	12 months
"Other," please explain	N/A
d. On average, what percentage of the FFS population is in Lock-In status annually?	1.0000%
e. Please provide an estimate of the savings attributed to the Lock-In program for the fiscal year under review as part of Attachment 5.	\$1.00
3. Do you have a documented process in place that identifies possible fraud or abuse of controlled drugs by prescribers?	Yes
If "Yes," what actions does this process initiate? Check all that apply:	Deny claims written by this prescriber, Refer to Program Integrity Unit, Refer to the appropriate Medical Board
"Other," please explain	N/A

Question	Response
4. Do you have a documented process in place that identifies potential fraud or abuse of controlled drugs by pharmacy providers?	Yes
If "Yes," what actions does this process initiate? Check all that apply:	Deny claim, Refer to Program Integrity Unit, Refer to Board of Pharmacy, Other
"Other," please explain	Pharmacy will be referred for audit; we have an active pharmacy audit program; explanation of benefit surveys to patients regarding pharmacy claims. Over 300 desk and field audits conducted in FY2018.
5. Do you have a documented process in place that identifies and/or prevents potential fraud or abuse of non-controlled drugs by beneficiaries?	Yes
"Yes," please explain your program for fraud, waste, or abuse of non-controlled substances.	Deny claims and require prior authorization; quantity limits; refer to Program Integrity

B. PRESCRIPTION DRUG MONITORING PROGRAM (PDMP)

Question	Response
1. Does your state have a Prescription Drug Monitoring Program (PDMP)? If the answer to question 1 is "Yes," please continue with a, b, and c.	Yes
a. Does your agency have the ability to query the state's PDMP database? If the answer to sub-question 1 a is "Yes," please continue.	Yes
i. Please explain how the state applies this information to control fraud and abuse.	Assessment for Lock-In Program
ii. Do you also have access to border states' PDMP information?	No
iii. Do you also have PDMP data (i.e. outside of MMIS, such as a controlled substance that was paid for by using cash) integrated into your POS edits?	No
b. Do you require prescribers (in your provider agreement with the agency) to access the PDMP patient history before prescribing controlled substances?	Yes
c. Are there barriers that hinder the agency from fully accessing the PDMP that prevent the program from being utilized the way it was intended to be to curb abuse?	Yes

Question	Response
“Yes,” please explain the barriers (i.e. lag time in prescription data being submitted, prescribers not accessing, pharmacists unable to view prescription history before filling script).	Limited to claim-level detail (cannot query by prescriber) and must have an NPI to access PDMP.
2. Have you had any changes to your state's Prescription Drug Monitoring Program during this reporting period that have improved the agency's ability to access PDMP data?	No
“Yes,” please explain.	N/A

C. PAIN MANAGEMENT CONTROLS

Question	Response
1. Does your program obtain the DEA Active Controlled Substance Registrant's File in order to identify prescribers not authorized to prescribe controlled drugs? If the answer to question 1 is “Yes,” please continue.	No
a. Do you apply this DEA file to your ProDUR POS edits to prevent unauthorized prescribing?	N/A
If “Yes,” please explain how information is applied.	N/A
If “No,” do you plan to obtain the DEA Active Controlled Substance Registrant's file and apply it to your POS edits?	N/A
b. Do you apply this DEA file to your RetroDUR reviews?	N/A
If “Yes,” please explain how information is applied.	N/A
2. Do you have a measure (i.e. prior authorization, quantity limits) in place to either monitor or manage the prescribing of methadone for pain management?	Yes
If “No,” please explain why you do not have measures in place to either manage or monitor the prescribing of methadone for pain management.	N/A

D. OPIOIDS

Question	Response
1. Do you currently have a POS edit in place to limit the quantity dispensed of an initial opioid prescription? If the answer to question 1 is “Yes, for all opioids” or “Yes, for some opioids,” please continue.	Yes, for all opioids
a. Is there more than one quantity limit for the various opioids?	Yes
“Yes,” please explain	Quantity limit varies based on drug, duration of action (e.g., short-acting vs. long-acting), and drug strength.
b. What is your maximum number of days allowed for an initial opioid prescription?	30
c. Does this day limit apply to all opioid prescriptions?	Yes
“No,” please explain	N/A
2. For subsequent prescriptions, do you have POS edits in place to limit the quantity dispensed of short-acting opioids?	Yes
If “Yes,” what is your maximum days supply per prescription limitation?	30 day supply
“Other,” please explain	N/A
3. Do you currently have POS edits in place to limit the quantity dispensed of long-acting opioids?	Yes
If “Yes,” what is your maximum days supply per prescription limitation?	30 day supply
“Other,” please explain	N/A
4. Do you have measures other than restricted quantities and days supply in place to either monitor or manage the prescribing of opioids?	Yes
If “Yes,” check all that apply:	Pharmacist override, Deny claim and require PA, Intervention letters, Morphine equivalent daily dose (MEDD) program, Step therapy or clinical criteria, Requirement that patient has a pain management contract or Patient-Provider agreement, Requirement that prescriber has an opioid treatment plan for patients, Require documentation of urine drug screening results
“Other,” please explain what additional opioid prescribing controls are in place.	N/A

Question	Response
If “No,” please explain what you do in lieu of the above or why you do not have measures in place to either manage or monitor the prescribing of opioids.	N/A
5. Do you currently have edits in place to monitor opioids and benzodiazepines being used concurrently?	No
If “Yes,” please explain	N/A
6. Do you perform any RetroDUR activity and/or provider education in regard to beneficiaries with a diagnosis or history of opioid use disorder (OUD), or opioid poisoning diagnosis?	Yes
If “Yes,” please indicate how often	Annually
Other, please explain	N/A
If “No,” do you plan on implementing a RetroDUR activity and/or provider education in regard to beneficiaries with a diagnosis or history of OUD, or opioid poisoning in the future?	N/A
7. Does your state Medicaid agency develop and provide prescribers with pain management or opioid prescribing guidelines?	No
For either “Yes” or “No,” please check all that apply:	Your state Medicaid agency refers prescribers to the CDC's Guideline for Prescribing Opioids for Chronic Pain.
Please identify the "referred" guidelines.	CDC Guidelines for Prescribing Opioids for Chronic Pain
Please identify the “other” guidelines.	N/A
8. Do you have a drug utilization management strategy that supports abuse deterrent opioid use to prevent opioid misuse and abuse (i.e. presence of an abuse deterrent opioid with preferred status on your preferred drug list)?	Yes
If “Yes,” please explain	Abuse deterrent opioids present on preferred drug list with preferred status.

E. MORPHINE EQUIVALENT DAILY DOSE (MEDD)

Question	Response
1. Have you set recommended maximum morphine equivalent daily dose measures? If “Yes,” please continue	No

Question	Response
a. What is your maximum morphine equivalent daily dose limit in milligrams?	N/A mg per day
b. Please explain (i.e. are you in the process of tapering patients to achieve this limit?).	N/A
If “No,” please explain the measure or program you utilize.	Quantity limits are currently in place, but not based upon a pre-specified morphine equivalent daily dose.
2. Do you provide information to your prescribers on how to calculate the morphine equivalent daily dosage or do you provide a calculator developed elsewhere? If “Yes,” please continue	No
a. Please name the developer of the calculator:	N/A
b. How is the information disseminated? Check all that apply:	N/A
If “Other,” please explain	N/A
3. Do you have an edit in your POS system that alerts the pharmacy provider that the morphine equivalent daily dose prescribed has been exceeded?	No
If “Yes,” do you require prior authorization if the MEDD limit is exceeded?	N/A

F. BUPRENORPHINE, NALOXONE, BUPRENORPHINE/NALOXONE COMBINATIONS and METHADONE for OPIOID USE DISORDER (OUD)

Question	Response
1. Does your agency set total mg per day limits on the use of buprenorphine and buprenorphine/naloxone combination drugs?	Yes
If “Yes,” please specify the total mg/day:	24 mg
If “Other,” please explain	N/A
2. What are your limitations on the allowable length of this treatment?	No limit
If “Other,” please explain	N/A
3. Do you require that the maximum mg per day allowable be reduced after a set period of time? If “Yes,” please continue	No
a. What is your reduced (maintenance) dosage?	N/A
If “Other,” please explain	N/A

Question	Response
b. What are your limitations on the allowable length of the reduced dosage treatment?	N/A
If "Other," please explain	N/A
4. Do you have at least one buprenorphine/naloxone combination product available without prior authorization?	Yes
5. Do you currently have edits in place to monitor opioids being used concurrently with any buprenorphine drug?	Yes
"Other," please explain	N/A
If "Yes," can the POS pharmacist override the edit?	No
6. Do you have at least one naloxone opioid overdose product available without prior authorization?	Yes
7. Does your state board of pharmacy and/or state Medicaid agency allow pharmacists to dispense naloxone prescribed independently or by collaborative practice agreements, standing orders, or other predetermined protocols?	Yes
8. Does your state agency cover Methadone for a substance use disorder (i.e. Methadone Treatment Center)?	Yes

G. ANTIPSYCHOTICS / STIMULANTS

ANTIPSYCHOTICS

Question	Response
1. Do you currently have restrictions in place to limit the quantity of antipsychotics? Enter restrictions other than quantity limits in the text box below, or N/A.	Yes
Please explain	Clinical prior authorization also in place for certain antipsychotics. Pediatric off-label use of antipsychotics reviewed on case-by-case basis.
2. Do you have a documented program in place to either manage or monitor the appropriate use of antipsychotic drugs in children? If "Yes," please continue	Yes

Question	Response
a. Do you either manage or monitor:	All children
“Other,” please explain	N/A
b. Do you have edits in place to monitor (check all that apply):	Child's Age, Dosage
“Other,” please explain	N/A
c. Please briefly explain the specifics of your antipsychotic monitoring program(s).	All pediatric use of antipsychotics requires submission for review using a Atypical Antipsychotic PA Form. The requests are reviewed on a case-by-case basis by a clinical pharmacist.
If “No,” do you plan on implementing a program in the future?	N/A
If “No,” please explain why you will not be implementing a program to monitor the appropriate use of antipsychotic drugs in children.	N/A

STIMULANTS

Question	Response
3. Do you currently have restrictions in place to limit the quantity of stimulants?	Yes
4. Do you have a documented program in place to either manage or monitor the appropriate use of stimulant drugs in children? If “Yes,” please continue	Yes
a. Do you either manage or monitor:	All children
“Other,” please explain	N/A
b. Do you have edits in place to monitor (check all that apply):	Child's Age, Dosage
c. Please briefly explain the specifics of your documented stimulant monitoring program(s).	Quantity limits, clinical prior authorizations, age requirements in place for stimulants.
If “No,” do you plan on implementing a program in the future?	N/A
If “No,” please explain why you will not be implementing a program to monitor the appropriate use of stimulant drugs in children	N/A

Section IX - INNOVATIVE PRACTICES

Question	Response
1. Attachment 6 – Innovative Practices Narrative	Yes

Question	Response
Have you developed any innovative practices during the past year (i.e. Substance Use Disorder, Hepatitis C, Cystic Fibrosis, MEDD, Value Based Purchasing)? Please describe in detailed narrative form any innovative practices that you believe have improved the administration of your DUR program, the appropriateness of prescription drug use and/or have helped to control costs (i.e., disease management, academic detailing, automated prior authorizations, continuing education programs). Does the state have Attachment 6 described above to upload?	

Section X - E-PRESCRIBING

Question	Response
1. Does your MMIS or pharmacy vendor have a portal to electronically provide patient drug history data and pharmacy coverage limitations to a prescriber prior to prescribing upon inquiry?	Yes
If "Yes," do you have a methodology to evaluate the effectiveness of providing drug information and medication history prior to prescribing? Please explain the evaluation methodology in Attachment 7 – E-Prescribing Activity Summary. Describe all development and implementation plans/accomplishments in the area of e-prescribing. Include any evaluation of the effectiveness of this technology (i.e., number of prescribers e-prescribing, percent e-prescriptions to total prescriptions, relative cost savings).	No
If "No," are you planning to develop this capability?	N/A
2. Does your system use the NCPDP Origin Code that indicates the prescription source?	Yes

Section XI - MANAGED CARE ORGANIZATIONS (MCOs)

Question	Response
1. How many MCOs are enrolled in your state Medicaid program?	4
2. Is your pharmacy program included in the capitation rate (carved in)?	Yes
If "Partial," please specify the drug categories that are carved out.	N/A

Question	Response
3. Does the state set requirements for the MCO's pharmacy benefit (e.g. same PDL, same ProDUR/RetroDUR)? If "Yes," please continue.	No
a. Please check all requirements that apply below:	N/A
b. Please briefly explain your policy.	N/A
If "No," do you plan to set standards in the future?	Yes
4. Did all of your managed care plans submit their DUR reports?	Yes
If "No," please explain why.	N/A

Section XII – EXECUTIVE SUMMARY

1. Attachment 8 – Executive Summary